Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
BioNTech SE
Astellas Pharma Inc
Boehringer Ingelheim
National Cancer Institute (NCI)
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Janssen Research & Development, LLC
AstraZeneca
RayzeBio, Inc.
Amgen
Genmab
Dana-Farber Cancer Institute
Seagen Inc.
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
City of Hope Medical Center
AstraZeneca
Zai Lab (Hong Kong), Ltd.
University of Chicago
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Debiopharm International SA
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
NRG Oncology
Merck Sharp & Dohme LLC
Eli Lilly and Company
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Inhibrx Biosciences, Inc
Eli Lilly and Company
Pfizer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of California, Irvine
City of Hope Medical Center
RemeGen Co., Ltd.
Amgen
Pfizer
BeOne Medicines
M.D. Anderson Cancer Center
University of Maryland, Baltimore
Washington University School of Medicine
Merck Sharp & Dohme LLC
AstraZeneca
University of Oklahoma
HC Biopharma Inc.
NRG Oncology
Roswell Park Cancer Institute